"/>
STEMCELL Technologies LY2228820 (Dimesylate) | B-LABO France
STEMCELL Technologies LY2228820 (Dimesylate)
Réf. : BL-RE-151707Réf. fabricant : 17110342 5 mg
140,40 € HT
p38 MAP kinase (MAPK) inhibitor
CAS
862507-23-1
Synonyme
Ralimetinib Mesylate; LSN2322600
Quantité
5 mg
Formule moléculaire
C24H29FN6 · 2CH3SO3H
Pureté
≥98%
Marque
STEMCELL Technologies
Caractéristiques principales
LY2228820 is a trisubstituted imidazole derivative and a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) in vitro (IC50 = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities (Campbell et al.) This product is supplied as the dimesylate salt of the molecule
Combined with other small molecule inhibitors such as Rapamycin (Catalog #73362) and SR1 (Catalog #72342; Li et al.) or SB203580 (Catalog #72222), Vx702, and BIRB-796 (Catalog #72682), enhances the self-renewal of cord blood-derived hematopoietic stem cells (Baudet et al.)
By inhibiting p38 MAPK, which is highly expressed in human cancers, LY2228820 is potent and selective at inhibiting tumor growth in animal models of a variety of human cancers (Campbell et al.)
